Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Studies Gene Therapy Compound As Vessel For Peripheral Growth

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' legacy as a Baxter spin-off is allowing the cardiovascular firm to pursue clinical applications of a peripheral artery disease (PAD) gene therapy compound without integrating it with a device

You may also be interested in...



Edwards Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman

Early clinical data profiling Edwards/Sangamo's EW-A-401 gene therapy for intermittent claudication (leg pain) in patients at the National Institutes of Health are expected to appear in the Oct. 19 issue of Circulation

Edwards Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman

Early clinical data profiling Edwards/Sangamo's EW-A-401 gene therapy for intermittent claudication (leg pain) in patients at the National Institutes of Health are expected to appear in the Oct. 19 issue of Circulation

Edwards’ drug/device combo

Edwards Lifesciences will integrate the EW-A-401 peripheral artery disease therapy with a catheter delivery system upon completion of an investigational new drug trial to evaluate efficacy of the compound, the firm clarifies Sept. 7 (1"The Gray Sheet" Sept. 6, 2004, p. 13). The catheter, which will treat cardiac ischemia, marks the firm's first drug/device combo product...

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel